Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis
Alan Menter, Tina Bhutani, Benjamin D. Ehst, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 6, pp. 1289-1302
Open Access | Times Cited: 14

Showing 14 citing articles:

Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial
Yukari Okubo, Satomi Kobayashi, Masamoto Murakami, et al.
American Journal of Clinical Dermatology (2024)
Open Access | Times Cited: 7
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement
Maria Concetta Fargnoli, Federico Bardazzi, Luca Bianchi, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 10, pp. 3545-3545
Open Access | Times Cited: 11
Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study
Giovanni Fiorillo, Luciano Ibba, Luigi Gargiulo, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 2, pp. 186-186
Open Access | Times Cited: 3
Clinical effectiveness of IL-17 and IL-23 inhibitors on difficult-to-treat psoriasis areas (scalp, genital, and palmoplantar sites): a retrospective, observational, single-center, real-life study
Luca Mastorino, Lorenza Burzi, Paolo Frigatti, et al.
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 9, pp. 929-936
Closed Access | Times Cited: 7
Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
Sara Cacciapuoti, Luca Potestio, Gianluca Guerrasio, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 2637-2644
Open Access | Times Cited: 7
Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses
Mark Lebwohl, April W. Armstrong, Andrew Alexis, et al.
Dermatology and Therapy (2024)
Open Access | Times Cited: 2
Brodalumab in the Treatment of Plaque Psoriasis Localized in Difficult-to-Treat Areas: a Narrative Review
Maria Vittoria Cannizzaro, Giulia Coscarella, Andrea Chiricozzi
Dermatology Practical & Conceptual (2023), pp. e2023245-e2023245
Open Access | Times Cited: 4
Palmoplantar psoriasis or palmoplantar keratoderma? Successful treatment with brodalumab
Dario Buononato, Caterina M. Giorgio, Emma Carraturo, et al.
International Journal of Dermatology (2024) Vol. 63, Iss. 9, pp. 1272-1273
Closed Access | Times Cited: 1
Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population
Antonio Sahuquillo‐Torralba, Mercedes Hospital‐Gil, E. Vilarrasa‐Rull, et al.
Australasian Journal of Dermatology (2023) Vol. 64, Iss. 4
Closed Access | Times Cited: 3
Effectiveness of Brodalumab on Scalp, Palmoplantar, and Genital Psoriasis: A Descriptive Pilot Study
Luca Mastorino, Valentina Celoria, Nicole Macagno, et al.
Dermatologic Therapy (2023) Vol. 2023, Iss. 1
Open Access | Times Cited: 2
A Phase IIIb, Multicentre, Interventional, Randomised, Placebo‐Controlled Clinical Trial Investigating the Efficacy and Safety of Guselkumab for the Treatment of Nonpustular Palmoplantar Psoriasis (G‐PLUS)
Thierry Passeron, J.M. Carrascosa, Richard B. Warren, et al.
Dermatologic Therapy (2023) Vol. 2023, Iss. 1
Open Access | Times Cited: 2
Characterization of psoriasis patients in special body areas: real-world evidence from the Chinese Psoriasis Standardized Diagnosis and Treatment Center
Yuge Gao, Chao Li, Meng Tong, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access
Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate to severe plaque psoriasis
Paolo Dapavo, Matteo Megna, Mark S. Talamonti
Dermatology Reports (2024)
Open Access
Comparative efficacy of ligelizumab versus omalizumab in chronic spontaneous urticaria
Sarah Moussa, Elena Netchiporouk
The Lancet (2023) Vol. 403, Iss. 10422, pp. 118-119
Closed Access | Times Cited: 1
Page 1

Scroll to top